Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Emergent Biosolutions, Inc. (F/K/A Adapt Pharma Inc.)
Lobbying Relationship
Bills mentioned
H.R.5046: Comprehensive Opioid Abuse Reduction Act of 2016
Sponsor: F. James Sensenbrenner (R-Wis.)
S.524: Comprehensive Addiction and Recovery Act of 2016
Sponsor: Sheldon Whitehouse (D-R.I.)
H.R.6: SUPPORT for Patients and Communities Act
Sponsor: Greg Walden (R-Ore.)
S.3120: HEAL Act of 2018
Sponsor: Orrin G. Hatch (R-Utah)
H.R.5925: CRISIS Act
Sponsor: Trey Gowdy (R-S.C.)
H.R.5590: Opioid Addiction Action Plan Act
Sponsor: Adam Kinzinger (R-Ill.)
H.R.5774: Combating Opioid Abuse for Care in Hospitals Act of 2018
Sponsor: Carlos Curbelo (R-Fla.)
S.3158: Departments of Labor, Health and Human Services, and Education, and...
Sponsor: Roy Blunt (R-Mo.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Deborah Burrell | Chief of Staff, Rep. Roscoe Bartlett. |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate